| Name | Title | Contact Details |
|---|---|---|
Steven Yannelli |
Director of Application Security and Compliance | Profile |
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
Global Animal Management is a Union, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fagron NV is a publicly traded multinational group of companies governed by Belgian law.
Sunovion Pharmaceuticals Inc., known until October 12, 2010 as Sepracor, Inc.
EMR Innovations is a Saint Cloud, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.